Bausch Health Companies (BHC) Accumulated Expenses (2009 - 2026)
Bausch Health Companies (BHC) reported Accumulated Expenses of $3.0 billion for Q1 2026, down 9.45% on a YoY basis from $3.4 billion in Q1 2025, and down 9.18% sequentially from $3.3 billion in Q4 2025.
Bausch Health Companies (BHC) Accumulated Expenses (2009 - 2026) Analysis & Trends
Bausch Health Companies (BHC) has 18 years of Accumulated Expenses data on file, last reported at $3.0 billion in Q1 2026.
- For the quarter ending Q1 2026, Accumulated Expenses fell 9.45% year-over-year to $3.0 billion; the trailing twelve-month figure through Mar 2026 stood at $3.0 billion (down 9.45% YoY), and the FY2025 full-year result was $3.3 billion, down 4.16% from the prior year.
- Accumulated Expenses fell to $3.0 billion in Q1 2026, from $3.3 billion in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $4.3 billion in Q2 2022 to a low of $2.9 billion in Q1 2023.
- A 5-year average of $3.4 billion and a median of $3.3 billion in 2024 frame the typical range for Accumulated Expenses.
- Across the five-year window, Accumulated Expenses plunged 41.11% in 2022 and rose 11.36% in 2024, its largest moves.
- Tracing BHC's Accumulated Expenses over 5 years: stood at $3.0 billion in 2022, then increased by 4.85% to $3.1 billion in 2023, then grew by 11.36% to $3.5 billion in 2024, then declined by 4.16% to $3.3 billion in 2025, then dropped by 9.18% to $3.0 billion in 2026.
- Business Quant data shows BHC's Accumulated Expenses at $3.0 billion in Q1 2026, $3.3 billion in Q4 2025, and $3.6 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Bausch Health Companies | 1.66 Bn | 1.33 Bn | 2.52 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.04 Bn |
| Dec 31, 2025 | 3.34 Bn |
| Sep 30, 2025 | 3.60 Bn |
| Jun 30, 2025 | 3.47 Bn |
| Mar 31, 2025 | 3.35 Bn |
| Dec 31, 2024 | 3.49 Bn |
| Sep 30, 2024 | 3.39 Bn |
| Jun 30, 2024 | 3.34 Bn |
| Mar 31, 2024 | 3.23 Bn |
| Dec 31, 2023 | 3.13 Bn |
| Sep 30, 2023 | 3.12 Bn |
| Jun 30, 2023 | 3.01 Bn |
| Mar 31, 2023 | 2.92 Bn |
| Dec 31, 2022 | 2.99 Bn |
| Sep 30, 2022 | 2.93 Bn |
| Jun 30, 2022 | 4.31 Bn |
| Mar 31, 2022 | 4.30 Bn |
| Dec 31, 2021 | 4.79 Bn |
| Sep 30, 2021 | 4.98 Bn |
| Jun 30, 2021 | 5.08 Bn |